Gomez-Piña et al., Supplemental Figure S1

A

ttol = 8 h trec = 16 h

LPS

tst

LPS

Analysis (tol)

tst

LPS

Analysis (c)

B

D

*

*

IL12p35/p70IL10

c c + LPS tol + LPS0

10

20

30

40

Po

sit

ive

ce

lls

(%)

C

**

c c + LPS tol + LPS0

100

200

300TNFIL6

[Pro

tein

] (n

g/m

l)

CD89 CD16b CD1a CD3 CD19 CD140

20

40

60

80

100

Po

sit

ive

ce

lls

(%)

Gomez-Piña et al., Supplemental Figure S2

c c+ LPS tol + LPS tol + LPS (GM6001)

0

2

4

6

81

3

6

18

24

48 h

[IL

6/ -

ac

tin

] x

10

-1

c c+ LPS tol + LPS tol + LPS (GM6001)

0

1

2

3

41

3

6

18

24

48 h

[IL

23

p1

9/ -

ac

tin

] x

10

-1

*

* *

*

**

*

*

*

*

* *

A

B

Gomez-Piña et al., Supplemental Figure S3

c s'TREM-1 (50 ng/ml)

c s'TREM-1 (10 ng/ml)

s'TREM-1 (50 ng/ml)

0

1

2

3

436 h

[TN

F

/-a

ctin

] x

10

+LPS

c s'TREM-1 (50 ng/ml)

c s'TREM-1 (10 ng/ml)

s'TREM-1(50 ng/ml)

0.0

0.5

1.0

1.5

2.0

2.536 h

[IL

12

p4

0/ -

act

in]

x 1

0-2

+LPS

+LPS

c s'TREM-1(50 ng/ml)

c s'TREM-1 (10 ng/ml)

s'TREM-1 (50 ng/ml)

0.0

0.5

1.0

1.5

2.0

2.536 h

[IL

10

/

-act

in]

x 1

0-2

A

B

C

**

**

*

**